Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 22, 2007

AstraZeneca Invests $100M in Boston R&D Center

  • AstraZeneca made a $100-million investment to expand its R&D facility in Boston, which is focused on infectious diseases and cancer. "This investment will significantly boost our research capabilities in two critical areas of medical need," says David Brennan, CEO. "It will provide additional resources for our scientists who are tackling more complex diseases than ever before, as they work towards our ultimate goal of giving people hope for a healthier future."

    AstraZeneca believes that Boston gives the company access to the leading scientific talent, potential partners and collaborators, and emerging science in a worldwide biotechnology hub.

    The company predicts that construction of the 132,000-sq-ft facility will begin at the Waltham, MA, site during the first quarter of 2007 and will be complete by mid 2009. The total size of the research facility will then be 382,000 sq. ft. The expanded facility will thus be able to accommodate up to 100 additional researchers.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »